Internal working note. The loop-4 accountability pass. The week's reader story lives in the Monday flagship brief (2026-07-13-market-brief); this is the part that is about us, not about the market, and it stays off the reader surface by design.

The finding: every mover we didn't own was already in our watchlists. Not one of the 19 unclaimed misses was a coverage gap — we had eyes on all of them. Two, TXG (+47%) and ABSI (+63%), are named in the biotech-capital-cycle roster itself: our own thesis, our own list, no position.

That distinction is the whole autopsy:

• A coverage miss means we never saw it. The fix is a watchlist row.
• A conviction miss means we saw it, wrote it up, and passed. The fix is a written trigger — or an honest "not our game."

Every item below is the second kind. The pipeline scores bad buys and never bad passes, which is precisely the drift this pass exists to catch.

The defense of the pass is real, and it's in the tape

Of the entire 981-name universe, exactly seven names trip the overextension screen — and all seven are the exhaustion kind: RSI above 70 while relative volume sits below 1×. TXG at RSI 72 on 0.82× volume; KYMR 71 on 0.50×; DAVE 0.45×; DFTX 0.53×. Zero qualify as the healthy, volume-backed kind. The parabolas we declined are running on fumes, exactly where the June thesis said the extended mid-caps would end up.

The indictment is also real

"We were right to be careful" and "we never wrote down what would make us act" are both true, and only one of them is a strategy.

The thesis called the theme, chose the conservative expression, and then left the aggressive expression with no entry condition at all — so the answer was never no, it was nothing. That is how a good call turns into a watched one.

The fix is not a new thesis. It is an expression ladder for the one we have — a written trigger for the mid-cap leg (base, reclaim of a rising average, volume confirmation) so the next TXG resolves to a documented yes or a documented no, instead of silence.

Follow-through

• Write the mid-cap entry trigger into biotech-capital-cycle — the lane has a thesis, a roster and a cohort verdict, but no entry conditions. #follow-up
• Give KYMR / RARE / VKTX / AGIO a real look. They were never argued, only never picked up. #follow-up
• Next read: MEDP Q2 book-to-bill, late this month — the domino this thesis has been waiting on since June.

---

Movers, exhaustion readings and cohort membership from an internal tape refresh (data as of the 2026-07-10 close) and the desk's own standing screens over the same bucket. The June "extended mid-cap" verdict and roster from the biotech-capital-cycle perspective record (2026-06-04).